Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 367, Issue 3, 2003, Pages 312-317

  Hropot, M ^a   Langer, K H ^a   Wiemer, Gabriele ^a   Grotsch H ^a   Linz, W ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Angiotensin II subtype AT1 receptor blocker; Fonsartan (HR 720); Losartan; NO synthase inhibition; Rat

Indexed keywords

2 BUTYL 4 METHYLTHIO 1 [[2' [[[(PROPYLAMINO)CARBONYL]AMINO]SULFONYL][1,1' BIPHENYL] 4 YL]METHYL] 1H IMIDAZOLE 5 CARBOXYLIC ACID; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATINE KINASE; CREATINE PHOSPHATE; FONSARTAN; GLYCOGEN; LACTATE DEHYDROGENASE; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATROPHY; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HYALINE DEGENERATION; HYPERTENSION; ISOLATED HEART; KIDNEY FAILURE; KIDNEY PLASMA FLOW; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PROTEIN URINE LEVEL; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; GLOMERULAR FILTRATION RATE; HEART; HYPERTENSION; IMIDAZOLES; KIDNEY; KIDNEY FAILURE; LOSARTAN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; VENTRICULAR FIBRILLATION;

EID: 0037356324     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0682-3     Document Type: Article

References (33)

1. Arnal J-F, Warin L, Michel J-B (1992) Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90:647-652
2. Barrels H, Böhmer M, Heierli C (1972) Serum Kreatininbestimmung ohne Enteiweissen. Clin Chim Acta 37:193-197
3. Baylis Ch, Mitruka B, Deng A (1992) Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281
4. Bouin P (1897) Etudes sur l'évolution normale et l'involution du tube seminifère. Arch Anat Microsc 1:225-339
5. Bravo R, Somoza B, Ruiz-Gayo M, Gonzalez C, Ruilope LM, Fernandez-Alfonso MS (2001) Differential effect of chronic antihypertensive treatment on vascular smooth muscle cell phenotype in spontaneously hypertensive rats. Hypertension 37:e4-e10
6. Brunner HR, Nussberger J, Waeber B (1993) Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens [Suppl 3] 11:S53-S58
7. Burnier M (2001) Angiotensin II type 1 receptor blockers. Circulation 103:904-912
8. Deprez P, Guillaume J, Becker R, Corbier A, Didierlaurent S, Fortin M, Frechet D, Hamon G, Heckmann B, Heitsch H, Kleemann H-W, Vevert J-P, Vincent J-C, Wagner A, Zhang J (1995) Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists: discovery of a highly potent orally active (imidazolylbiphenylyl) sulfonylurea (HR 720). J Med Chem 38:2357-2377
9. Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T (1996) Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 28:397-402
10. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31:349-355
11. Hropot M, Grötsch H, Klaus E, Langer KH, Linz W, Wiemer G, Schölkens BA (1994) Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn-Schmiedeberg's Arch Pharmacol 350:646-652
12. Khaper N, Singal PK (2001) Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 37:1461-1466
13. Korth P, Fink E, Linz W, Schölkens BA, Wohlfart P, Wiemer G (1995) Angiotensin II receptor subtype-stimulated formation of endothelial cyclic GMP and prostacyclin is accompanied by an enhanced release of endogenous kinins. Pharm Pharmacol Lett 5:124-127
14. Küng CF, Moreau P, Takase H, Lüscher TF (1995) L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Hypertension 26:744-751
15. Lindholm L, Ibsen H, Dahlöff B, Devreux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson D, Lederballe-Pederson O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group (2002) Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004-1010
16. Linz W, Schölkens BA, Han Y-F (1986) Beneficial effects of the converting enzyme inhibitor ramipril in ischaemic rat hearts. J Cardiovasc Pharmacol 8 [Suppl 10]:S91-S99
17. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47:25-49
18. Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G (1999) Interactions among ACE, kinins and NO. Cardiovasc Res 43:549-561
19. Linz W, Heitsch H, Schölkens BA, Wiemer G (2000) Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension 35:908-913
20. Lüscher TF (1993) The endothelium as a target and mediator of cardiovascular disease. Eur J Clin Invest 23:670-685
21. Morton JJ, Beattie EC, Speirs A, Gulliver F (1993) Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens 11:1083-1088
22. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ (1993) Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21:660-666
23. Rees DD, Palmer RMJ, Moncada S (1989) Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci 86:3375-3378
24. Regitz-Zagrosek V, Neuss M, Holzmeister J, Fleck E (1995) Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. J Hypertens 13 [Suppl 1]:563-571
25. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R (1992) Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20:298-303
26. Salazar FJ, Pinilla JM, Lopez F, Romero JC, Quesade T (1992) Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension 20:113-117
27. Schelling P, Fischer H, Ganten D (1991) Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 9:3-15
28. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Gräber M (1945) The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 24:288-293
29. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tnaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104:925-935
30. Walser M, Douglas G, Davidson G, Orloff J (1955) The renal clearance of alkali-stable inulin. J Clin Invest 34:1520-1523
31. Yang Y, Macdonald GJ, Duggan KA (1996) A study of angiotensin II receptors after chronic inhibition of nitric oxide synthase in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 23:441-443
32. Yusuf S (2002) From the HOPE to the ONTARGET and TRANSCEND studies: challenge in improving prognosis. Am J Cardiol (Suppl) 89:18A-26A
33. Zatz R, de Nucci G (1991) Effects of acute nitric oxide inhibition of rat glomerular microcirculation. Am J Physiol 30:F360-F363